Condition 1: Delirium. Condition 2: Agitation. Delirium due to known physiological condition Restlessness and agitation
Conditions
Interventions
Intervention 1: Intervention group: In addition to the essential and standard treatment for delirium, two tablets of Melatonin 3 mg (Razak pharmaceutical company), once daily at 9 P.M., will be admini
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 18 years or older Hospitalization in the intensive care unit with delirium receiving quetiapine Normal gastrointestinal function to receive medication by the mouth or other enteral routes Capability to follow the patient for at least 7 days Full consent and acceptance of the patient or their legal guardian to recruit in the study
Exclusion criteria
Exclusion criteria: Patients with GCS= 8 History of severe melatonin allergy History of epilepsy or seizures Chronic heart failure ( New York Heart Association classification III/IV ) The patient's Richmond Agitation-Sedation Scale (RASS) is about -4 or -5 Head trauma History of delirium or mood changes before admission to the ICU
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement of patient's delirium. Timepoint: Daily from the beginning of the study. Method of measurement: CAM-ICU questionnaire for delirium.;Agitation. Timepoint: Daily from the beginning of the study. Method of measurement: Richmond agitation sedation scale score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShadi Farsaei
Esfahan University of Medical Sciences
Outcome results
None listed